Larimar Therapeutics
LRMR • NASDAQ
Larimar Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Carole S. Ben-Maimon, with a market cap of $479.9M.
CEOCarole S. Ben-Maimon
Next Earnings
Upcoming earnings announcement for Larimar Therapeutics
Date
Wednesday, April 29, 2026 (in 4 weeks)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.60
Earnings History
Past 12 earnings reports for Larimar Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | Q4 2025 | -$0.73Est: -$0.50 | -46.0% | - | — |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.61Est: -$0.41 | -48.8% | - | — | 10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.41Est: -$0.48 | +14.6% | - | — | 10-Q |
| Apr 30, 2025 | Q1 2025 | -$0.46Est: -$0.41 | -12.2% | - | — | 10-Q |
| Mar 24, 2025 | Q4 2024 | -$0.45Est: -$0.32 | -40.6% | - | — | 10-K |
| Oct 30, 2024 | Q3 2024 | -$0.24Est: -$0.37 | +35.1% | - | — | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.34Est: -$0.30 | -13.3% | - | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.27Est: -$0.24 | -12.5% | - | — | 10-Q |
| Mar 14, 2024 | Q4 2023 | -$0.30Est: -$0.25 | -20.0% | - | — | 10-K |
| Nov 14, 2023 | Q3 2023 | -$0.21Est: -$0.22 | +4.5% | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.19Est: -$0.19 | 0.0% | - | — | 10-Q |
| May 15, 2023 | Q1 2023 | -$0.15Est: -$0.25 | +40.0% | - | — | — |